Shares of Incyte have moved 6.2% today, and are now trading at a price of $97.98. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 2,183,166 compared to the stock's average volume of 1,475,866.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. Based in Wilmington, United States the company has 2,844 full time employees and a market cap of $19,574,657,024.
The company is now trading -9.24% away from its average analyst target price of $107.96 per share. The 24 analysts following the stock have set target prices ranging from $71.0 to $135.0, and on average give Incyte a rating of buy.
Over the last 52 weeks, INCY stock has risen 36.8%, which amounts to a 9.4% difference compared to the S&P 500. The stock's 52 week high is $112.29 whereas its 52 week low is $66.3 per share. Based on Incyte's average net margin growth of 21.9% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2025 | 5,141,242 | 1,286,650 | 25 | 2400.0 |
| 2024 | 4,241,217 | 32,615 | 1 | -93.75 |
| 2023 | 3,695,649 | 597,599 | 16 | 60.0 |
| 2022 | 3,394,635 | 340,660 | 10 | -68.75 |
| 2021 | 2,986,267 | 948,581 | 32 | 390.91 |
| 2020 | 2,666,702 | -295,697 | -11 |
